Approbation of the iimiquimod-induced psoriasislike skin inflammation in BALB/с mice

Abstract

Background.Antipsoriatic medicines that have been successfully tested by imiquimod-induced psoriasislike skin inflammation in BALB/c mice may be used for therapy of psoriasis induced by the immune response as inflammatory cascade into skin layers.Objective.Imiquimod-induced psoriasis-like skin inflammation approbation in BALB/c mice and search of more informative method of pathologic progress assessment for further extrapolating data to clinical cases.Design and methods. Psoriasis-like skin inflammation in mice was induced by topical applying of the Aldara® cream (5 % imiquimod) to back skin for 7 days. Psoriasis Area and Severity Index (PASI), histological study, calculation of relative spleen and thymus mass to the body weight, hematological analysis and skin disease area determination were used for registration of pathologic building.Results.During the study, was detected the increase of PASI score of animals with pathology to 18 with the formation of psoriasis-like plaques, significantly decrease body weight and relative thymus mass, significantly increase relative spleen mass, leukocytosis and leukocytic blood profile change, significant increase epidermal thickness, hyperkeratosis and inflammatory infiltration different degree.Conclusion.Results of approbation studied pathologic model with using of hematological analysis and skin disease area determination consistent with similar studies’ data and partly clinical sings in patient with psoriasis.